REFERENCES

Abo-Salem L.Y., (2000): Self-care program for children suffering from β thalassemia major. Doctorate thesis, Faculty of Nursing, Alexandria University; pp.: 1-55.

Acklin P. and Helv C., (2005): Iron chelation therapy. Acta; 83:677-686.

Adamkiewicz T.V.; Berkovitch M. and Krishnan C., (2001): Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis.; 27: 1362.

Adewoye A.V. and Steinberg M.H., (2004): Thalassemia in R.E. Rakel and E.T. Bope, Conn's Current Therapy, W.B. Saunders, USA; pp.:414-419.

Advani R.; Sorenson S.; Shinar E.; Lande W.; Rachmilewitz E. and Schrier S.L., (1999): Characterization and comparison of the red blood cell membrane damage in severe human α- and β-thalassemia. Blood; 79:1058-1063.

Aessopos A.; Farmkis D. and Karagiorga M., (2001): Cardiac involvement in thalassemia intermedia a multicenter studies. Blood; 97: 3411-3418.

Agnello L., (2007): Thalassemia. Diseases and Conditions. Available at: http://health.discovery.com/encyclo/illnesses.html

Ahmed S.; Saleem M.; Modell B. and Petrou M., (2002): Screening extended families for genetic hemoglobin disorders in Pakistan. N Engl J Med; 347: 1162-1168.

Aldudak B.; Karabay B.; Noyan A.; Ozel A.; Anarat A.; Sasmaz I.; Kiline Y.; Gali E.; Anarat R. and Dikmen N., 2000): Renal function in pediatric patients with beta-thalassemia major. Pediatric Nephrology; 15(1-2): 109-112.

Aliberti B.; Patrikiou A.; Terentiou A.; Frangatou S. and Papadimitriau A., (2001): Spinal cord compression due to extramedullary hematopoiesis in patients with thalassemia. J of Neurology; 248(1): 18-22.

Alp M.; Cohen A.; Eleftheriou A.; Piga A. and Porter J., (2001): Endocrine complications in thalassemia major in: Guidelines for the Clinical Management of Thalassemia. TIF; 4-49.

Al-Salem A.H; Naserullah Z. and Qaisaruddin A., (1999): Splenic complications of the sickling syndromes and the role of splenectomy. J Pediatr Hematol Oncology; 21:401-406.

Al-Suliman A., (2006): Prevalence of β –thalassemia trait in premarital screening in Al-Hassa, Saudi Arabia. Ann Saudi Med; 26(1):14-16.

Alwan A. and Modell B., (2003): Recommendations for introducing genetics services in developing countries. Nat Rev Genet; 4: 61-68.

American Association for Clinical Chemistry (AACC), (2009): Thalassemia. Available at: http://www.labtestsonline.org/ understanding/conditions/thalassemia-2.html

American Pregnancy Association (APA), (2006): Amniocentesis. Available at:

http://www.americanpregnancy.org/prenataltesting/amniocentesis.html

Anderson L.J.; Wonke B.; Prescott E.; Holden S.; Walker J.M. and Pennell D.J., (2002): Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet; 360: 516-520.

Anie K.A. and Massuglia P., (2001): Psychological therapies for thalassemia: Cochrane Database Syst. Rev.; 3: CD002890.

Antai-Otong D. and Kongable G., (2005): Psychiatric Nursing, Biological and Behavioral Concepts. W.B. Saunders Co., London; p.: 572.

Appelbaum F.R., (2001): Critical care nursing. 4th ed., W.B. Saunders Co., London; p.: 1332.

Ausiello G., (2002): Cecil, Textbook of Medicine. 2nd ed., W.B Saunders Co., London; pp.: 959-965.

Aydinok Y.; Erermis S.; Bukusoglu N.; Yilmaz D. and Solak U., (2005): Psychosocial implications of thalassemia major.Pediatr Int; 47: 84 – 89.

Behrman R.E.; Kilegman R.M. and Jenson H.B., (2004): Nelson Textbook of Pediatrics. 17th ed., W.B. Saunders Co., London; pp.: 32, 38, 1483-1489.

Benz E.J. and Giardina P.J., (1999): Thalassemia syndromes In D.R. Miller and R.L. Baehner, Blood diseases of infancy and childhood. 7th ed., Mosby, Boston; pp.: 460, 482.

Benz E.J.; Braunwald S.L.; Hauser A.S.; Fauci D.I. and Kasperz M., (2001): In E. Braunwald; S.L., Hauser; A.S. Fauci; D.L. Kasper; S.L. Hauser; D.L. Longo and J.L. Jameson, Harrison's Principles of International Medicine. 15th ed., McGraw-Hill, New York; pp.: 666, 667-673.

Beratis S., (1999): Psychological status in pre-adolescent children with β thalassemia. J Psychosomatic Res.; 37(3): 271-279.

Bibi S.; Ali A.; Habiballah M.; Latif G.; Taghi M.; Arzanian M.; Samin A.; Hossein E.; Farnoush G. and Reyhaneh A., (2008): Sensory Neural Hearing Loss in β-Thalassemia Major Children Treated With Deferoxamine. Pediatric Hematology and Oncology:

Incorporating the International J Pediatr Hematol Oncology; 1521-0669; 25(6): 502 –508.

Bonetti M.G.; Cashivta S.A.; Criconia G.M. and Mazza P., (1999): Hepatic iron overload in thalassemic patients: proposal and validation of MRI method of assessment. Pediatric Radiology; 26(9): 650-656.

Borgna-Pignatti C., (2007): Surviving with thalassemia major. Pediatric Hematology oncology; 24(1): 75-78.

Bryant R., (2005): In Wong's Essentials of Pediatric Nursing. 7th ed., Mosby, USA; pp.: 949-951.

Burns C.E.; Dunn A.M.; Brady M.A.; Starr M.B. and Blosser C.C., (2004): Pediatric Primary Care, 3rd ed., Saunders, USA, p.: 45.

Cambell S. and Glasper E.A., (1999): Whaley and Wing's, Children Nursing. Mosby, London, pp.: 105-107.

Cao A. and Galanello R., (2002): Effect of consanguinity on screening for thalassemia. N Engl J Med; 347:1200-1202.

Cappellini M.; Bejaoui M. and Perrotta S., (2004): Phase III evaluation of once-daily, oral therapy with ICL670

(Exjade) versus deferoxamine in patients with β-thalassemia and transfusional hemosiderosis. Blood;104, 984.

Carolgreen-Hernandez C.; Joannek S.; Nielz A. and Danielz A., (2001): Primary care pediatric. 6th ed., pp.:496,497.

Castiglia P.T. and Harbin R.E., (2004): Child Health Care. Process and Practice.28th ed., J.B. Lippincott Co., Philadelphia; pp.: 621-624

Ceci A.; Baiardi P. and Felisi M., (2002): The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol; 118: 330-336.

Chan Y.L.; Li C.k.; Pang L.M. and Chik K.W., (2000): Desferrioxarnine-induced long bone changes in thalassaemic patients-Radiolographic feature, prevalence and rotation with growth; clinical Radiography; 55(8): 610-614.

Cheng C.N.; Lu C.C. and Sunny H.F., (2002): Successful matched unrelated bone marrow transplantation in a patient with β–thalassemia major. Journal of Pediatric Hematology/Oncology; 24(7): 579-581.

Cherchi C.B.; Pacifico L.; Cossellu S.; Gallisai D.; Zanetti S.; Fadda G. and Chiesa C., (2000): Prospective study of Yersinia enterocolitica infection in thalassemic patients. Pediatr Infect Dis J.; 14(7): 579-584.

Cheuk D.K.; Mok A.S.; Lee A.C.; Chiang A.K.; Ha S.Y. and Lau Y.L., (2008): Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant; 42: 319 – 27.

Choi S.; Chung C.; Kim H.; Lee S.; Yoon S. and Kho H., (2003): Factors affecting the quality of life in patient's with thalassemia in South Korea. Acta; 108: 428-434.

Christy L. and Jon B., (2004): Strategies and Innovations for Successful Quality Improvement in Behavioral Health. Journal of Nursing Care Quality; 19(3): 197-206.

Chui D. H. K.; Cunningham M.J.; Luo H.-y.; Wolfe L. C.; Neufeld E. J. and Steinberg M. H., (2006): Screening and counseling for thalassemia. Blood; 107: 1735-1737

Chutima M.; Chung-Yung J. L.; Ruchaneekorn W. K.; Pornpan S.; Prapin W.; Suthat F. and Barry H.

(2007): Elevated F2-isoprostanes in thalassemic patients. Doi: 10.1016/J. Institute Science Technology for Research and Development; 43(12): 1649-1655.

Clark G.M. and Higgins T.N., (2000): Laboratory investigations of hemoglobinopathies and thalassemia: Review and Update. Clinical Chemistry; 49: 1284-1290.

Clark N.; Jones P.; Keller S. and Verineire P., (1999): Patient factors and compliance with asthma therapy. Respiratory Medicine, London; 93: 856-862.

Clemente, c., j. Tsiandis, i. Kolvin, et al. 2003. Social adjustment in three cultures: data from families affected by chronic blood disorders. A sibling study. Haemophilia 9: 317–324.

Cochrane G.M.; Horne R. and Chancz P., (1999): Compliance in asthma respiratory medicine. France; 93: 763-769.

Cohen A.R.; Galanello R.; Pennell D.J.; Cunningham M.J. and Vichinsky E. (2004): Thalassemia. Hematology (Am Soc Hematol Educ Program); 1: 14-34.

Colin A. and Wilson T., (2004): Quality of Life and Psychosocial Developments of children with thalassemia; 16: 513-518. **Cooley's Anaemia Foundation, (2009):** Thalassemia. 9th Cooley's Anemia Symposium. http://www.thalassemia.org/

Crain M.; Jaswon M.S. and Chew E., (1999): Management of chronic disease. Eur. J Pediatr. 155: 326-329.

Craven R.F. and Hirnle C.J., (2002): Nursing care plans. 3rd ed., J.B. Lippincott, New York; pp.: 744, 746.

Cunningham M.J.; Macklin E.A.; Neufeld E.J. and Cohen A.R., (2004): Complications of β-thalassaemia major in North America. Blood; 104(1): 34–39.

De-Sanctis. V., (2002): Growth and puberty and its management in thalassaemia. Horm Res; 58 Suppl 1:72–79.

Devinsky O.; Westbrook L.; Gramer J.; Glassman M. and Camfield C., (1999): Risk Factors for Poor Health-Related Quality of Life in Adolescents with thalassemia; 40: 1715-1720.

Dimopolou I.; Kremastinos D.T.; Maris G.; Mavrogeni S. and Tzelepsis E., (1999): Respiratory fuction in

patients with thalassemia and iron overload, Eur. Respir. J.; 13(3): 602-605.

Dines M.D; Canale V.C. and Arnold W.D., (2009): Prognosis of Thalassemia. J of Bone and Joint Surgery; 12:19-21. www.wrongdiagnosis.com/t/thalassemia/prognosis.htm

Dorothy E.N. and Marlow M.B., (2006): Hematologic disease pediatric primary care. 3th ed., W.B. Saunders Co., p.: 455-456.

Dubey A.P.; Parakh A. and Dublish S., (2008): Current trends in the management of β thalassemia. Indian J Pediatr; 75(7): 739-743.

Dworkin P.H., (2000): Pediatrics. 4th ed., Lippincott William and Wilkins, New York, pp.: 492,493.

Edlin G.; Golanty S. and Brown K.M., (2002): Health and Wellness. 7th ed., Jones and Bartlett Publishers, London, p.: 332.

Edward J.B.; Stanley L.S. and Stephen A.L., (2009): Molecular pathology of thalassemic syndromes. **http://www.uptodate.com/patients/content/topic.do**

Eileen R. and Angelo P., (2003): Nursing Approach to the evaluation of child mal-treatment, 1st ed., Louis Medical Co., 58-63.

EI-Naggar M., (2005): Short Atlas in Pediatrics. 1st ed., University Book Center, Egypt, P. 62.

Eiser C.; Mohay H. and Morse R., (2000): The measurement of Quality of Life in Young Children. Child Care Health Dev; 26: 401-414.

El Beshlawy A., (2004): Prevention of β-thalassemia in Egypt. The15th Annual Conference of the Egyptian Medical Syndicate "Preventive Medicine; pp.: 31, 32.

El-Awamy B.H. and Pearson H.A., (2001): Thalassemia syndromes in Saudi Arabia: Meta-analysis of local studies. Saudi Med J.; 21:8-17.

El-Awamy B.H.; Al-Mulhim T.A.; Flemban S.B. and Al-Naeem S.A., (2002): Evaluation of current management of homozygous **β** -thalassemia in Eastern Saudi Arabia. Saudi Arabia Med J.; 23(9):1141-1142.

El-Awamy T., (2002): Nutritional program for children with **β- thalassemia major and their mothers.** Doctorate

thesis, Faculty of Nursing, Ain Shams University; pp.: 32-35.

El-Beshlawy A.; Kaddah N.; Ragab L. and Hussein J., (1999): Thalassemia prevalence and status in Egypt Pediatric Research, 45(5): 102-117.

El-Beshlawy, A. (2003): Study of blood levels of glucose and insulin in Egyptian thalassemic not known to be diabetics. Unpublished Research, New children Hospital, Faculty ofMedicine, Cairo University; pp.: 3-5.

Eldor A. and Rachmilewitz E.A., (2002): The hypercoagulable state in thalassemia. Blood; 99(1): 36-43.

Eldor A.; Durst R.; Hy-Am E.; Goldfarb A.; Gillis S.; Rachmilewilewitz E.A.; Abramov A.; Maclouf J.; Goedfrauy Y.; De Raucourt E. and Gullin M.C., (1999): A chronic hypercoagulable state in patients with β- thalassemia major. Br. J. Hematol.; 107(4): 739.

El-Gawhary S.; Elbaradie M.Y. ; Rashad W. M.; Mosaad M. ; Abdalla M. A. .; Ezzat G.; Wali

Y. A. and Elbeshlawy A., (2009): Prenata Diagnosis of β-Thalassemia in Egypt: Implementing Accurate High-Tech Methods Did not Reflect Much on the Outcome. Doi: 10.1080/08880010802313509. Pediatr Hematol and Oncology; 25(6): 541 – 548.

Elliott, B.; Gallery, P. and Mould. J. In E.A. Glasper; J. Richardson (2006): A Textbook of Children Young People's Nursing. 1st ed., Churchill Livingstone. Elsevier, London, PP.: 725, 726.

El-Tahan H.M., (2004): Principles of pediatrics. 1st ed., Medical Book Center, Mansoura University, PP. 171-177.

Fadel A.A., (2001): Bone marrow transplantation adnsensity in Egyptian thalassemic children: Effect of chelation, Master Thesis, Faculty of Medicine, Alexandria University; PP.: 1-23.

Fiorelli G.; Fargion S.D.; Piperno A. and Battafarano N., (1999): Iron metabolism in thalassemia intermedia Hematology, 75(5): 89.

Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga (2003): A. Monitoring long-term efficacy of iron

chelation therapy by deferiprone and desferrioxamine in patients with beta thalassaemia major: Application of SQUID biomagnetic liver susceptometry. Br J Haematol 121: 938–948.

Franchini M. and Veneri D., (2004): Iron-chelation therapy: an update. Hematol J; 5:287-292.

Franchini M.; Boyden H. and Hrrison P., (2000): Benefits of chelation therapy in β thalassemia. Semin haematol; 33: 315-317.

Fuchs G.J.; Tienboon P.; Linpisarn S.; Mimsakul S.; Leelapat P.; Tovanobutra S.; Tubtong V.; De Wier A. and Suskind R.M., (1999): Nutritional factors and thalassemia major. Arch. Dis. Child.; 74: 224-227.

Galanello R.; Piga A.; Alberti D.; Rouan M.C.; Bigler H. and Sechaud R., (2003): Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol; 43: 565 - 572.

Gedikoglu G., (2001): Bone marrow transplantation in thalassemia. Bone Marrow Transplant; 28(2): 1-10.

Genetics Home References, (2009): β-thalassamia. Available at: http://ghr.nlm.nih.gov/condition=betathalassemia

George, E.; Jamal, A. and Khalid, F., (2001): High Performance Liquid Chromatography (HPLC) as a Screening Tool for Classical Beta Thalassaemia Trait in Malaysia. Malaysian J of Medical Sciences. 8:40-46.

Giardina P.J. and Grady R.W., (2001): Chelation therapy in β-thalassamia: An optimistic update. Seminar Hematology, 38: 360-366.

Gibson B.E.; Todd A. and Roberts I., (2004): Transfusion guidelines for neonates and older children. Br J Hematology; 124(4):433-53.

Golan E., (2009): Pathology, 2nd ed., Mosby Elsevier, Rapid Review Series. Available at: http://en.wikipedia.org/wiki/Thalassemia

Goldbeck L.; Baving A. and Kohne E., (2000): [Psychosocial aspects of beta-thalassemia: distress, coping and adherence]. Klinische Padiatrie; 212: 254–259.

Gomella T., (2004): Neonatology management, procedure on-call problems, diseases, and drugs 5th ed., A Simon and Schuster comp. p. 43-44, 166-169, 326-327.

Greenberg S.,(2009).http://www.utoronto.ca/kids/Thalassemia.htm

Guidelines for the Clinical Management of Thalassemia (GCMT), (2008): Thalassemia Standards of Care. Available at: http://www.thalassemia.com/SOC_guidelines.html

Guidelines for the Clinical Management of Thalassemia (GCMT), Thalassemia International Foundation (TIF), (2000): Management of Hemoglobin Disorders; pp.: 25, 26. Available at: http://www.ncbi.nlm.nih.gov/bookshelf/br.

Hacker E.D. and Ferrans C.E., (2005): Quality of life immediately after peripheral blood stem cell transplantation. Cancer Nursing; 26(4): 312-322.

Harrison P.M., (2000): Ferritin: an iron storage molecule. Semin. Hematol; pp.: 214: 55.

Hay M..; Coupta M..; Levin M.J. and Paul M., (2002): Ghai essential pediatric. 6th ed., New Delhi; p: 553.

Health Education Center, (2008): Thalassemia. Available at: http://www.marchofdimes.com/pnhec/4439_1229.asp

Health Guide, (2008): Thalassemia Available at: http://health. nytimes.com/health/guides/disease/thalassemia/overview.html

Hershko C.; Graham G.; Bates G.W. and Rachmilewitz E.A., (1999): Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol; 40: 255-263.

Hershko C.; Link G.M.; Konijn A.M. and Cabantchik Z.I., (2005): Iron chelation therapy. Current Hematology, 4: 110-6.

Higgs D.R. and Bowden D.K., (2001): Clinical and laboratory features of the β-thalassemia syndromes. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology,

and Clinical Management. Cambridge, UK: Cambridge University Press; pp.: 431–469.

Higgs D.R.; Thein S.L. and Woods W.G. (2001): The molecular pathology of thalassemia In DJ. Weatheral and B. Clegg, The thalassemia syndromes. 4th ed., Oxford, Blackwell Science; pp.: 133-91.

Hoffbrand A.V.; Cohen A. and Hershko C., (2003): Role of deferiprone in chelation therapy for transfusional iron overload. Blood; 102: 17-24.

Hollenstein J. and Puzanov I., (2009): Thalassemia. Available at: http://images.google.com/imgres?imgurl.

Hollenstein J., (2008): Thalassemia (Mediterranean Anemia, Cooley's anemia, Thalassemia Major, Thalassemia Minor). Available at: http://www.thirdage.com/health-wellness/thalassemia-mediterranean-anemia-cooleys-nemia-thalassemia-major-thalassemia-minor

Holmes S. and Dickerson J., (2003): The quality of life: design and evaluation of a self- assessment instrument for use with cancer patients. International Journal of Nursing Studies; pp.: 40,515-520.

Honig, G.R., (2000): Hemoglobin disorders in R.E. Behrman; R.M. Kliegman and H.B. Jenson, Nelson, Textbook of Pediatrics. 16th ed., W.B. Saunders Co., London; pp.: 1479, 1484-1487.

Hood C. and Dincher M., (2005): Pediatric hematology. 2nd ed., W.B. Saunders Co., London; pp.:753-755.

Hussein I.R.; El-Beshlawy A. and Temtomy S., (2000): Prevention of β thalassemia in Egypt by carrier detection and prenatal diagnosis, for the 2nd ed., workshop on prenatal diagnosis of thalassemia.

Incorvaia C.; Parmeggiani F.; Costagliola C.; Perri P; D'Angelo S. and Sebastiani, A., (2003): Qualitative evaluation of the retinal venous tortuosity in chronic anemia patients affected by β thalassemia major. Eye; 17(3): 324-329.

International Council of Nursing, (2005): Assessment of knowledge and practice of nurses about their care of children who are suffering from hemolytic anemia, blood; 25: 353.

Ismail A.; Campbell M.J.; Ibrahim H.M. and Jones G.L., (2006): Health related quality of life in Malaysian

children with thalassemia. Health Quality of Life Outcomes; 4: 39.

Johnson K.B. and Oski F.A., (1999): Oski's, Essential Pediatrics. Lippincott Raven, Philadelphia, pp.: 347-349.

Karimi M.; Asadi-Pooya A.A. and Khademi B (2002): Evaluation of the incidence of sensorineural hearing loss in beta thalassemia major patients under regular chelation therapy with deferrioxamine. Acta Hematology; 108(2): 79-83.

Karnon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. (1999): Lifetime treatment costs of β-thalassaemia major. Clin Lab Haematol; 21:377-385.

Katzos G.; Papakostantinou-Althanasiadau E.; Althanasiadau-Metaea M. and Marsoulis F., (2000): Growth hormone treatment in short children with β-thalassaemia major. J Pediatr Endocrinol Metab.; 13(2): 163-170.

Kenner R. and Madaren S., (2004): Pediatric nursing. 2nd ed.Lippincott, Williams Wilkins, New York; pp.: 330-333.

Khateeb B.; Moatter T.; Shaghil A.M.; Haroon S. and Kakepoto G.N. (2000): genetic diversity of β-thalassaemia mutations in Pakistani population. Journal of Pakistani Medical Association, 50(9): 293-296.

King C.R. and Hinds P., (2007): Quality of life: "From nursing and patient perspectives" 2nd ed., theory, research, practices. Boston, Jones and Bartlett Publishers; pp.: 3-29.

King M.W., (2009): Medical Biochemical page control of thalassemia.
http://images.google.com/imgres?imgurl=http://themedicalbiochemistrypage.org/images/hemoglobin.jpg&imgrefurl-

Kuo H.T.; Tsai M.Y.; Peng C.T. and Wu K.H. (2006): Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan. *Hemoglobin*; 30:291–299.

Kuypers F.A. and De Jong K. (2004): The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol; 50: 147-158.

Kyngas H., (2005): Compliance of adolescents with chronic disease. Clinical Nursing, 9(4): 549-556.

Ladis V.; Papatheodorou A.; Berdousi H. and Palamidou F., (2005): Psychological problems affect the quality of life of thalassemic patients. Ann N Y Acad Sci.; 1054:40-47.

Lanzlowsky P.H, (2000): Hemoglobin defects, thalassemia, Manual of Pediatric Hematology and Oncology, 3rd ed., Churchill Livingstone. New York, London and Tokyo; pp. 182-191.

Lanzlowsky P.H., (2005): Manual of pediatric hematology and oncology. Elsevier, Academic Press, New York, pp.: 181-194.

Li Q.; Li L.Y. and Mo Q.H., (2008): [A rare thalassemia intermedia case caused by co-existence of Hb H disease -and beta-thalassemia major: implications for prenatal diagnosis]. Nan Fang Yi Ke Da Xue Xue Bao.; 28(1):16-9.

Lichtman M. and Shafer A., (2007): Atlas of Hematology. Available at: http://www. Accessmedicine.com/.

Link G., Konin A.M.; Breue W.; Cabantchik Z.L. and Hershko C., (2001): Exploring the (iron shuttle) hypothesis in chetation therapy: Effects of combined deferroxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and iron loadedrat heart cell in culture. J Laboratory Clinical Medicine; 138: 130-138.

Lo L. and Singer S.T., (2002): Thalassemia: current approach to an old disease. Pediatr Clin North Am. Dec; 49(6):1165-91.

Lo L.; Quirolo K.C. and Vichinsky E.P., (2001): Thalassemia In H.F. Conn; R.E. Rackel and E.T. Bope, Conn's current Therapy. W.B. Saunders Co., U.S.A.; pp.:389-394.

Lorin D.W.; Meador K.J and Lee G.P., (2004): Determinants of Quality of Life in Thalassemia; 5: 976-980.

Lucarelli G.; Galimberti M. and Polchi P., (2003): Bone Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med.; 16; 329(12):840-4.

Mackensen S., (2007): Quality of life assessment in children and adolescents with hemophilia, at th5th international congress of ESPH, at Inter Continental-Heliopolis City Stars, Cairo Egypt, 29th-30th March.

Malik P., and Arumugam P.I., (2005): Gene Therapy for {beta}-Thalassemia. In: Hematology (Am Soc Hematol Educ Program); pp.: 45-50.

Margrate E., (2006): Allogenic bone marrow transplantation in hematologic disorders of childhood. New trands and controversies hematology; pp.: 70-72.

Marlow D.R. and Redding B.A., (2001): Textbook of pediatric. 1st ed., W.B. Saunders Co., Indian; pp.: 657-661.

Mayo Clinic Com., (2008): Amniocentesis. Available at: http://www.mayoclinic.com/health/amniocentesis/

Mclntosh N.; Helms P.J. and Smith R.L., (2003): Forfar and Arneil's, Textbook of pediatrics. 6th ed., Churchill Livingstone. London; pp.: 438-440, 1070-1073.

Medical Encyclopedia, (2009): Thalassemia. Available at: http://en.wikipedia.org/wiki/Thalassemia

Medicine Net com. (2009): Beta Thalassemia diagnosis. Available http://www.ehow.com/beta-thalassemia-diagnosis.

Michael C., (2006): Medical Encyclopedia. Thalassemia major. Philadelphia, PA. Available at: http://www.nlm.nih.gov/ medlineplus/imagepages/1498.htm.

Mikelli A. and Tsiantis J., (2004): Brief report: depressive symptoms and quality of life in adolescents with b-thalassaemia. J Adolesc*;* **27**: 213–216.

Miller R., (2008): What Are Thalassemias? Kids Health. Available at: http://kidshealth.org/parent/thalassemias.html

Miller R., (2008): What Are Thalassemias? Kids Health. Available at: http://kidshealth.org/parent/thalassemias.html

Miller S.T., (1999): Thalassemia In L.Finberg, Saunders Manual of Pediatric Practice. W.B. Saunders Co., London; pp.; 413-417.

Miller S.T.; Pharmd B. and Paap C.M., (1999): Current pediatric diagnosis and treatment. Pharmed; p.: 119.

Miller V.; Palermo T.M. and Grewe S.D., (2005): Quality of life in Pediatric Thalassemia; 4: 36-42.

Modell B.; Khan M. and Darlison M., (2000): Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet; 355: 2051-2052.

Mourad F.H.; Hoffbrand A.V.;, Sheikh-Taha M.; Koussa S.; Khoriaty A.I. and Taher A., (2003): Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol; 121: 187-189.

Nagy H.M., (2004): Management of Haemolytic Anemia in El-Galaa Family Hospital, Master Thesis, Faculty of Nussing, Cairo University; p.: 22.

Nathan DG, Oski FA., (1998): The thalassemia. In: Hematology of Infancy and Childhood. Philadelphia, Pa: WB Saunders Co; 1: 783-879, 811-886.

National Association of Nurses, (2005): Assessment knowledge and practice of nurses about their care of children who are suffering from hemolytic anemia; p.: 72.

National Heart Lung and Blood Institute Diseases and Conditions Index, (NHL and BID and CI), (2008): What is thalassemia? Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/ Thalassemia/html

National Institute of Health (NIH), (2008): Beta thalassessmia. Available at: http://www.nhlbi.nih.gov/health/dci/Diseases/Thalassemia/Tha-lassemia_WhatIs.htmlhttp://ghr.nlm.nih.gov/condition=betathalassa

Nisbet-Brown E.; Olivieri N.F. and Giardina P.J., (2003): Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet; 361: 1597-1602.

Old J.M.; Olivieri N.F. and Thein S.L., (2001):. Diagnosis and management of thalassaemia. In: Weatherall DJ, Clegg B, eds. The thalassaemia syndromes. 4th ed. Oxford, England: Blackwell Science; pp.: 630-85.

Olivieri N.F. and Brittenham G.M., (1999): Iron-chelating therapy and the treatment of thalassemia. Blood; 89: 739–761.

Olivieri N.F., (1999): The β-thalassemias. N Engl J Med; 341:99-109. [Erratum, N Engl J Med 1999; 341:1407.]

Olivieri N.F.; Brittenham G.M. and McLaren C.E., (1999): Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med.; 339(7):417-23.

Olivieri N.F.; Brown E.N.; Giardina P.G.; Grady R.W.; Newfeld E.J. and Sechoued R., (2003): Effectiveness and safety 1 cL 670 in iron loaded patients with thalassemia: A randomized Double-blind, Placebo-controlled. Dose escalation trial, The Lancet; 361: 1597-1602.

Orkin, S.H. and Nathan, D.G, (2003): The thalassemias in D. Nathan; S.H. Orkin; D. Ginsburg and A.T. Look and Oski's Hematology of Infancy and childhood. 6th ed., W.B. Saunders, Philadelphia, p.: 84.

Oyarabal M.; Aliaga M.; Chueca M. and Echarte G., (1999): Multi-centre survey on compliance with

growth hormone therapy. Acta Pediatric, Spain; 91: 387-391,

Paley C., (2000): Haemolytic anemia (thalassemias) in P. Lanzkowsky, (eds.), Manual of Pediatric Hematology and Oncology. 3rd ed., Academic Press, San Diego, p.: 250.

Papanikolaou G.; Tzilianos M. and Christakis J.I., (2005): Hepcidin in iron overload disorders. Blood; 105: 4103-4105.

Persons A.; Allay E.R.; Sawai N.; Hargrove P.W.; Brent T.P.; Hanawa H., Nienhuis A.W. and Sorrentino B.P., 2003): Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells Blood 2003 102:506-513.

Piatti G.; Allegra L.; Ambrosetti U.; Cappellini M.D.; Turati F. and Fiorelli G.; (1999): Beta-thalassemia and pulmonary function**.** Haematologica,; 84(9): 804-808.

Piga A., Longo F. and Duca L., (2009): High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol.; 84:29.

Pillitteri A., (2003): Maternal and child health nursing care of the child bearing and child rearing family. 4th ed., Lippincott Williams and Wilkins, New York, London; pp.: 1349-1352.

Pootrakul P.; Sirankapracha P. and Sankote J (2003): Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol; 122:305-310.

PORTER, J. & Berry.A. DAVIS. 2002. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract. Res. Clin. Haematol. 15: 329–368.

Protonotariou A.A. and Tolis G.J., (2000): Reproductive health in female patients with beta-thalassemia major. Ann NY Acad Sci.; 900:119-124.

Puthenveetil G. and Malik P., (2004): Gene therapy for hemoglobinopathies: are we there yet? Curr Hematol Rep; 3: 298-305.

Rachmilewitz E.A. and Schrier S., (2001): The pathophysiology of β-thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of hemoglobin: genetics, pathophysiology, and clinical management. Cambridge, England: Cambridge University Press; pp.: 233-51.

Rachmilewitz, E. and Rund, A (2005): Beta-thalassemia. NewEii Journal of Medicine, 353(11): 1139.

Rapkin B.D. and Schwartz C.E., (2004): Theoretical Model of Quality of Life Appraisal. Health and Quality of Life Outcomes; 2: 14.

Rodger G.P., (2000): In L. Goldman and J. C. Bennett, CECIL, Textbook of Medicine. 2nd ed., W.B. Saunders Co., London; 1: 885-887.

Rosina F., (2001): Comprehensive pediatric. 6th ed., Philadelphia: Lippincott Williams Co.,; pp.:234-242.

Savulescu J., (2004): Thalassemia major: The murky story of deferiprone. BMJ; pp.: 358-359.

Schrier S.L., (2002): Pathophysiology of thalassemia. Curr Opin Hematol.; 9:123–126.

Seashore M.R., (2000): Thalassemia In E.E. Rakel and E.T. Bope, Conn's Current Therapy. W.B. Saunders, U.S.A.; pp.: 415-421.

Shinar E.; Rachmilewitz E.A. and Lux S.E., (1999): Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J Clin Invest; 83: 404-410.

Simons M.R., (1999): Intervention related to compliance. Nursing Clincs of North America, 27(2): 477-494.

Singer S.T., (2004): Thalassemia In E.E. Rakel and E.T.Bope, Conn's, Current Therapy. Saunders, U.S.A.; pp.: 415-421.

Singer S.T.; Wu V. and Mignacca R., (2000): Alloimmunization and erythrocyte **autoimmunization in transfusion- dependent thalassemia** patients of predominantly asian descent. Blood; 96(10):3369-73.

Smeltezer S.C. and Bare B.G., (2004): Brunner and Sunddarth's, textbook of Medical Surgical Nursing. 10th ed., Lippincott Wialliams & Wilkins, New York; pp.: 124-128, 868 - 876.

Steinberg M.H. and Benz E.J., (2000): Pathobiology of the human erythrocyte and its hemoglobins. In: Hoffman, R, Benz, EJ, Shattil, SJ, et al (Eds). Hematology: Basic Principles and Practice, 3rd edition. Churchill Livingstone, Philadelphia; p.: 356.

Sungthong R.; Mo-suwan L.; Chongsuvivatwong V. and Geater A.F., (2002): *Once Weekly Is Superior to Daily Iron Supplementation on Height Gain but Not on Hematological Improvement among Schoolchildren in Thailand. The American Society for Nutritional Sciences J. Nutr.; 132: 418-422.*

Takeshita, K., (2007): Thalassemia, Beta. Available at: http://emedicine.medscape.com/article/206490-media.

Tassiopoulos S,; Deftereos S.; Konstantopoulos K.; Farmakis D.; Tsironi M.; Kyriakidis M. and Aessopos A., (2005): "Does heterozygous β-thalassemia confer a protection against coronary artery disease?". Ann N Y Acad Sci. 1053: 467–70.

Tavazzi D.; Duca L.; Graziadei G.; Comino A.; Fiorelli G. and Cappellini M.D., (2001): Membrane-bound iron contributes to oxidative damage of β-thalassemia intermedia erythrocytes. Br J Haematol; 112: 48-50.

Tefler P.; Constantinidou G.; Andreou P.; Christou S.; Modell B. and Angastiniotis M., (2005): Quality of Life in Thalassemia. Annals of the New York Academy of Science. 1054:273–282.

Thalassemia Foundation of Canada, (2007): Thalassemia. Available at: http://www. Thalassemia.ca.

Thein S.L., (2005):. Pathophysiology of {beta} Thalassemia--A Guide to Molecular Therapies. In: *Hematology (Am Soc Hematol Educ Program)*; pp.: 31-37.

Thuret I., (2001): Therapetic management of patient with **thalassemia major. Bull.Scc. Pathol. Ezat.; 94(2): 95-97.**

Tierney L.M.; McPhee S. J. and Papadakis M.A. (2004): Current Medical Diagnosis and treatmen, 43rd ed., McGraw-Hill, New York; pp.: 456-467.

Tsiantis, J., T. Dragonas, C. Richardson, et al. 2002. Psychosocial problems and adjustment of children with beta-thalassemia and their families. Eur. Child Adolesc. Psychiatry 5: 193–203

Uthman, ED., (2008): Hemoglobinopathies and Thalassemia Nature Medicine; 13: 1020–1021.

Varni, J.w., Burwinkle, T.M., Seid, M. (2006): The PedsQL 4.0 as a school population measure: Feasibility, reliability, and validity. Quality of Life Research, 15: 203-215.

Vichinsky E., (2005): In Northern Comprehensive Thalassemia Center. Available at: http://www.thalassemia.com/

Villeval C.; Kuntc A.; Kemth P. and Katz E., (2004): Therapeutic play and bone marrow transplantation, jof Ped Nurs.; pp.: 11-16.

Voskaridou E.; Terpos E.; Spina G.; Palermos J.; Rahemtulla A. and Loutradi A., (2003): Pamidronate is an effective treatment for osteoporosis in patients with beta thalassamia. Br J Haematol. 123: 730–737.

Weatherall D.J. and Clegg J.B. (2001): The Thalassamia Syndromes. 4th ed., Oxford: Blackwell Science.

Weatherall D.J. and Clegg J.B., (1999): Genetic disorders of hemoglobin. Semin Hematol.; 36(4): 24-37.

Weatherall, D.J. (2004): The Thalassamia: The Role of Molecular Genetics in an Evolving Global Health Problem. American Journal of Human Genetics. 74:385-392.

Whalley D.; Huels J.; Mckenna S.P. and Van Assche D., (2002): The benefit of pimecrolinmus on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics, 110(6): 1133-1136.

Wikipedia Project, (2009): Thalassemia .From Wikipedia, the free encyclopedia. http://en.wikipedia.org/wiki/Thalassemia

Will C., (2003): Medical Surgical Nursing. 9th ed., Lippincott Co., New York; pp.: 736-764.

Wong D.L.; Hess C.S. and Kasprisin C.A., (2000): Wong and Whaley's Clinical Manual of Pediatric Nursing. Mosby, Boston; p.: 343.

Wood W.G., (2001): Hereditary persistence of fetal hemoglobin and delta beta thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge, UK: Cambridge University Press; 356–388.

World Health Organization. 2005. Measuring Quality of Life. Available at: http://www.who.int/evidence/assessment-instruments/QOL/index.htm. (Last accessed: March 30, 2005)

Yaish H.M., (2005): Thalassemia. Available at: http://www.emedicine..com/

Yaish H.M., (2007): Various mutations in the gene that result in thalassemia. Available at: http://emedicine.medscape.com/article/ 958850-media

Yaish H.M., (2009): Thalassemia Intermedia: Treatment & Medication. Available at: http://emedicine.medscape.com/article/959122-treatment